On March 4, 2025 Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, reported that it will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025 (Press release, Evaxion Biotech, MAR 4, 2025, View Source [SID1234650878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evaxion will be providing company and scientific updates as well as engaging with different stakeholders at conferences in both the US and Europe. As such, conference participation is an important part of our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations.

Evaxion conference participation March-June 2025:

Immunotherapy and Immuno-Oncology Congress, March 12-14 – London

HC Wainwright AI Based Drug Discovery & Development Conference, April 2 – Virtual

Jones Healthcare and Technology Innovation Conference, April 8-9 – Las Vegas

World Vaccine Congress, April 21-25 – Washington

AACR Annual Meeting, April 25-30 – Chicago

Sidoti Micro-Cap Conference, May 20-21 – Virtual

Dark Genome Target Discovery & Development Summit, June 16-18 – Boston

BIO International Convention, June 16-19 – Boston

World Conference on Infectious Diseases, June 18-20 – Stockholm

International Neoantigen Summit, June 24-26 – Amsterdam

In addition to the list above, Evaxion will be participating, but not presenting, at additional conferences to further boost our stakeholder engagement. Please visit our website for more information.